{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:55:36Z","timestamp":1791060936439,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajpc.2026.101783","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:46:12Z","timestamp":1786059972000},"page":"101783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-792X","authenticated-orcid":false,"given":"Luke","family":"Laffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-0195","authenticated-orcid":false,"given":"Markus P.","family":"Schlaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy C.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallik","family":"Rettiganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen B.","family":"Dennehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4015-7794","authenticated-orcid":false,"given":"Bruno","family":"Linetzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10258","key":"10.1016\/j.ajpc.2026.101783_bib0001","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101783_bib0002","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jama.2020.14545","article-title":"Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018","volume":"324","author":"Muntner","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2026.101783_bib0003","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1016\/j.jacc.2018.10.022","article-title":"Reprint of: prevention and control of hypertension","volume":"72","author":"Carey","year":"2018","journal-title":"JACC"},{"key":"10.1016\/j.ajpc.2026.101783_bib0004","unstructured":"W. World Health Organization, Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight, 2025 (accessed 18-May-2025)."},{"issue":"6","key":"10.1016\/j.ajpc.2026.101783_bib0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101783_bib0006","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: mechanistic links","volume":"15","author":"Hall","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101783_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf218","article-title":"From pathophysiology to novel approaches for obesity-associated hypertension","volume":"18","author":"Kanbay","year":"2025","journal-title":"Clin Kidney J"},{"issue":"18","key":"10.1016\/j.ajpc.2026.101783_bib0008","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"86","author":"Jones","year":"2025","journal-title":"JACC"},{"issue":"38","key":"10.1016\/j.ajpc.2026.101783_bib0009","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2026.101783_bib0010","unstructured":"N. NICE guideline, Hypertension in adults: diagnosis and management. https:\/\/www.nice.org.uk\/guidance\/NG136, 2019 (accessed 18-May-2026)."},{"issue":"5","key":"10.1016\/j.ajpc.2026.101783_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/HYP.0000000000000202","article-title":"Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American heart association","volume":"78","author":"Hall","year":"2021","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101783_bib0012","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archinternmed.2009.470","article-title":"Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE Study","volume":"170","author":"Blumenthal","year":"2010","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.ajpc.2026.101783_bib0013","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/jama.279.11.839","article-title":"Sodium reduction and weight loss in the treatment of hypertension in older PersonsA randomized controlled trial of nonpharmacologic interventions in the elderly (TONE)","volume":"279","author":"Whelton","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101783_bib0014","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/HYPERTENSIONAHA.118.12290","article-title":"Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension","volume":"73","author":"Schiavon","year":"2019","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101783_bib0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized Controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabet Care"},{"issue":"10","key":"10.1016\/j.ajpc.2026.101783_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.122.19248","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.ajpc.2026.101783_bib0017","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101783_bib0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","article-title":"Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","volume":"22","author":"Lingvay","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101783_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamainternmed.2025.6112","article-title":"Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial","volume":"186","author":"Horn","year":"2026","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101783_bib0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCRESAHA.125.325676","article-title":"Obstructive sleep apnea and cardiometabolic disease: obesity, hypertension, and diabetes","volume":"137","author":"Tasali","year":"2025","journal-title":"Circ Res"},{"issue":"13","key":"10.1016\/j.ajpc.2026.101783_bib0021","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101783_bib0022","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40618-024-02459-3","article-title":"The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression","volume":"48","author":"Ala","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101783_bib0023","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40256-025-00738-9","article-title":"Meta-analysis of the effect of semaglutide on blood pressure in Obese populations","volume":"25","author":"Li","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ajpc.2026.101783_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4141117","article-title":"Abstract 4141117: semaglutide and cardiovascular outcomes by blood pressure in the SELECT trial","volume":"150","author":"Verma","year":"2024","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101783_bib0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","article-title":"The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis","volume":"83","author":"Wu","year":"2024","journal-title":"Endocrine"},{"issue":"10522","key":"10.1016\/j.ajpc.2026.101783_bib0026","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2026.101783_bib0027","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/s41591-026-04386-7","article-title":"Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial","volume":"32","author":"Aronne","year":"2026","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ajpc.2026.101783_bib0028","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist Orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajpc.2026.101783_bib0029","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajpc.2026.101783_bib0030","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2026.101783_bib0031","unstructured":"Stride BP, Validated devices for office \/clinic blood pressure measurement. https:\/\/www.stridebp.org\/office-hospital-pdf\/, 2026 (accessed)."},{"key":"10.1016\/j.ajpc.2026.101783_bib0032","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1111\/dom.70783","article-title":"Pharmacokinetic bioequivalence of Orforglipron tablets and capsules in healthy participants with obesity or overweight","volume":"28","author":"Ma","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"10400","key":"10.1016\/j.ajpc.2026.101783_bib0033","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"544","key":"10.1016\/j.ajpc.2026.101783_bib0034","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1080\/01621459.2022.2049278","article-title":"Toward better practice of covariate adjustment in analyzing randomized clinical trials","volume":"118","author":"Ye","year":"2023","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101783_bib0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/jch.14517","article-title":"Identifying and treating resistant hypertension in PRECISION: a randomized long-term clinical trial with aprocitentan","volume":"24","author":"Danaietash","year":"2022","journal-title":"J Clin Hypertens"},{"issue":"18","key":"10.1016\/j.ajpc.2026.101783_bib0036","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101783_bib0037","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ajpc.2026.101783_bib0038","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ajpc.2026.101783_bib0039","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of Baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101783_bib0040","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2026.101783_bib0041","series-title":"I. International Conference on Harmonisation","year":"2000"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726003570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726003570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:28:39Z","timestamp":1791059319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726003570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":41,"alternative-id":["S2666667726003570"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101783","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101783"}}